pensation or sepsis. Available therapeutic modalities for acute variceal bleeding include vasoactive drugs, balloon tamponade, endoscopic variceal ligation, sclerotherapy and portocaval shunting procedures. Recently, attention has focused on octreotide as a treatment modality for those bleeding from esophageal varices. The purpose of this review is to present the relevant clinical research on octreotide and suggest a rational approach to the use of this drug.
OCTREOTIDE, SOMATOSTATIN AND
PORTAL HEMODYNAMICS Octreotide is a synthetic analogue of naturally occurring somatostatin-14. In pharmacological doses this octapeptide inhibits gastrointestinal exocrine secretions and stimulates intraluminal fluid absorption (2, 3) . While the biological effects of this peptide are essentially those of native somatostatin, octreotide appears to be more potent and to have a dramatically longer half-life (4, 5) . Unlike somatostatin, octreotide can be administered subcutaneously.
Because of the inaccessibility of the portal vein in humans, indirect methods such as hepatic vein catheterization or Doppler flowmetry have been employed in the study of portal hemodynamics. In cirrhotic patients, several investigators (6-10) have observed a significant decrease in estimated portal venous pressure after administration of somatostatin and octreotide. This effect persisted for up to 3 h after the octreotide infusion was stopped (11) . The responsible mechanisms are unknown but may involve direct vasoconstriction of splanchnic vasculature, vasodilation of the portal system or inhibition of vasoactive hormones such as glucagon (12) . However, not all investigators have confirmed these pressure-related findings (13, 14) . For example, Lin et al (15) , in a study of 20 patients with hepatitis B cirrhosis, did not find any change in the hepatic venous pressure gradient after either low or high dose infusions of octreotide.
More consistent measurements have been observed using measurements of azygous vein flow, which reflects collateral and variceal bloodflow. Reproducible reductions in azygous bloodflow have resulted from both octreotide and somatostatin infusions (10, 16) . Intravariceal pressure can be measured using either fine needle puncture or compression techniques. A close correlation appears to exist between variceal bleeding events and elevated intravariceal pressure (17) . The effects of somatostatin or octreotide infusions on intravariceal pressure are under debate. Investigators have reported both increases and decreases in pressure during drug infusions (18) (19) (20) . The heterogeneity of these responses may be due to differences in measurement techniques, disease severity and/or systemic vascular effects of the drugs.
CLINICAL TRIALS WITH SOMATOSTATIN
AND OCTREOTIDE Clinical trials involving patients with acute bleeding from esophageal varices have evaluated the effects of somatostatin compared with those of placebo, vasopressin and injection sclerotherapy. In a randomized double-blind trial, Burroughs and co-workers (21) demonstrated that intrave-nous somatostatin (250 mg/h) over five days was superior to placebo in controlling initial hemorrhaging, as well as in reducing early rebleeding and transfusion requirements. Valenzuela et al (22) were unable to reproduce a therapeutic effect in a similarly designed trial; however, the high response rate (83%) in the placebo group suggests significant patient selection bias. A recent meta-analysis of published clinical trials examined the relative therapeutic efficacies of somatostatin and vasopressin. Somatostatin was more efficacious than vasopressin in controlling acute variceal hemorrhage; somatostatin also had a lower rate of adverse events (23) . Somatostatin compared favourably with balloon tamponade in the control of initial hemorrhage (24, 25) . In a study of 70 patients, Planas et al (26) demonstrated that somatostatin by infusion was as effective as injection sclerotherapy in both controlling initial bleeding episodes and preventing early rebleeding. Also, significantly fewer major complications were observed in the somatostatin group (26) .
An overview of published clinical trials on octreotide is found in Table 1 . In one study of 100 patients, Sung et al (27) demonstrated that octreotide was as effective as emergency sclerotherapy in controlling initial hemorrhage and preventing rebleeding episodes. In that trial the majority of rebleeding episodes occurred within 48 h of presentation. In a subsequent study, the same investigators demonstrated that octreotide in combination with endoscopic band ligation significantly reduced the incidence of early rebleeding over band ligation alone (28). Besson's group (29) found a significant reduction in early rebleeding in 199 patients when octreotide was combined with standard sclerotherapy (29) . McKee et al (30) found octreotide to be as effective as balloon tamponade in controlling initial hemorrhage. In an attempt to reduce rebleeding, Primignani et al (31) used subcutaneous injections of octreotide (300 mg/day) for up to 29 days after the initial bleeding episode had been controlled with endoscopic sclerotherapy. No difference in rebleeding rates was found between treatment or placebo groups; however, this lack of difference may be a function of the low dose used (31) . Octreotide has also been found to be more effective than vasopressin and its longer acting analogue terlipressin in controlling acute bleeding; as well, substantially fewer side effects were noted in the octreotide group (32) (33) (34) . In all of the studies cited above, no difference was seen in patient mortality between treatment groups. The exception was the study from McKee and colleagues (30) , which found a substantially higher mortality in the esophageal tamponade group.
AN APPROACH TO THE MANAGEMENT OF BLEEDING ESOPHAGEAL VARICES
The goals of treatment in acute variceal bleeding are to control the initial hemorrhage, prevent early rebleeding, minimize deterioration in liver function and treat complications associated with blood loss (35) . Priority is given to airway management, along with early establishment of good venous access. Resuscitation involves administration of intravenous Many centres favour endoscopic sclerotherapy or band ligation once the patient has been stabilized. The advantage to this approach is that the site of bleeding can be identified and the hemorrhage controlled in most instances. While endoscopic banding appears to be safer than injection sclerotherapy, banding is not always possible if the patient is bleeding briskly or visibility is poor (36, 37) . The main difficulty in banding or sclerotherapy is that endoscopy facilities are not available in many centres on an emergency basis. In addition, even in experienced hands rebleeding rates after sclerotherapy or banding are as high as 40% (36, 37) . Therefore, a therapeutic agent that can be easily administered while the patient is being stabilized and transferred to an endoscopy facility is necessary. Vasopressin has traditionally been used in this capacity. However, because of vasopressin's side effect profile and the need for concomitant nitroglycerin administration, investigators have continued to search for better vasoactive agents. Unfortunately, while synthetic analogues of vasopressin such as terlipressin have proven efficacious, they have also similar adverse effects (33, 38) .
As discussed earlier, somatostatin and octreotide have proven efficacy in controlling the initial hemorrhage and in preventing rebleeding events. Moreover, in clinical trials the side effect profiles of both somatostatin and octreotide are minimal. While no head-to-head trials have been performed on these two agents, available evidence suggests a similar therapeutic response. While the acquisition cost per microgram of both products is similar, the required dosage of somatostatin is five times that of octreotide (250 mg/h versus 50 mg/h). The cost in Canadian dollars for 48 h of treatment is $840.50 for somatostatin versus $252.52 for octreotide. Figure 1 presents an approach to therapy incorporating octreotide for the patient with suspected bleeding esophageal varices. It seems reasonable to begin octreotide at presentation for any patient with upper gastrointestinal hemorrhage who has a high clinical likelihood of bleeding esophageal varices. The drug can be given while the patient is being stabilized or during transfer to an endoscopy centre. If a nonvariceal bleeding lesion is found during endoscopy, the drug can be discontinued, although some investigators feel that there is evidence for efficacy with high risk bleeding peptic ulcers (39) . Following treatment with sclerotherapy or banding, octreotide should be continued for two to five days to prevent rebleeding episodes. For patients who experience further rebleeding, available treatment options include balloon tamponade, repeat endoscopic banding or portocaval shunting. It should be emphasized that octreotide should not be used as a substitute for timely and urgent endoscopy in the bleeding patient. Patients who fail to stabilize with appropriate resuscitation require urgent endoscopy, whether or not octreotide has been used.
CONCLUSIONS
Octreotide is a new peptide analogue effective in the treatment of bleeding esophageal varices. In clinical trials it has proven equivalence to esophageal banding in controlling initial hemorrhaging, and it is superior to banding alone in preventing rebleeding. It should be part of the therapeutic armamentarium of every Canadian hospital.
